Skip to main content
Biotest AG logo

Biotest AG — Investor Relations & Filings

Ticker · BIO3 ISIN · DE0005227201 LEI · 529900JVX7RPXBLYUD89 F Manufacturing
Open in API
Filings indexed 1,148 across all filing types
Latest filing 2024-09-05 Regulatory Filings
Country DE Germany
Listing F BIO3

About Biotest AG

https://www.biotest.com/de/en/index.cfm

Biotest AG is a global company that develops, manufactures, and supplies plasma protein products and biotherapeutic drugs. Sourced from human blood plasma, its products are primarily used in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. The portfolio includes immunoglobulins (e.g., Intratect), coagulation factors, and albumins designed to treat severe and chronic diseases such as immune deficiencies, haemophilia, and coagulation disorders. The company manages the entire value chain from clinical development to sales and is advancing a pipeline of new treatments, including next-generation immunoglobulins (BT595) and fibrinogen concentrates (BT524). Biotest also provides Human Serum Albumin for use as a multifunctional excipient in pharmaceutical and diagnostic applications.

Recent filings

Filing Released Lang Actions
Biotest AG opens 13th plasma collection center in Germany
Regulatory Filings Classification · 100% confidence The document is a press release dated September 5, 2024, announcing the opening of Biotest AG's 13th plasma collection center in Germany. It uses the header 'EQS-News' and is disseminated via 'EQS News – a service of EQS Group AG'. The content is operational news about facility expansion and supply chain management, not a formal financial report (like 10-K, IR, or ER), nor is it a proxy statement or management discussion. Since it is a general corporate announcement that doesn't fit the highly specific categories like DIRS, DIV, or CAP, it falls best under the general regulatory announcement category, which is RNS (Regulatory Filings) as the fallback for miscellaneous corporate news distributed via regulatory channels.
2024-09-05 English
Dr. Jorg Schuttrumpf resigns from the Management Board of Biotest AG
Board/Management Information Classification · 100% confidence The document is a press release announcing that Dr. Jörg Schüttrumpf is resigning from the Management Board of Biotest AG to focus on a role within the parent Grifols Group. The key phrase is 'Dr. Jörg Schüttrumpf resigns from the Management Board of Biotest AG' and the content details changes in senior management structure. This directly corresponds to the definition for Board/Management Information (MANG). The document length is short (4798 chars), but it is the primary announcement itself, not an announcement *about* a report, so the RPA/RNS rule does not apply here.
2024-08-28 English
Ergänzung der Veröffentlichung vom 03.05.2024
AGM Information Classification · 99% confidence The document is titled "Gewinnverwendungsbeschluss" (Resolution on the Appropriation of Profits) and details how the net profit for the fiscal year ending December 31, 2023, was allocated by the Annual General Meeting (Hauptversammlung) held on May 7, 2024. Specifically, it outlines the dividend distribution per share for preferred shares for 2023 and 2022, and the resulting retained earnings carried forward. This content directly relates to the formal decision regarding dividend payments made during or immediately following a shareholder meeting, which aligns best with the 'Notice of Dividend Amount' (DIV) category, as it specifies the exact dividend amounts decided upon. Although it stems from the AGM, the core subject is the dividend declaration.
2024-08-26 German
Biotest increases sales in the first half of 2024 by 35% to Euro 372 million
Earnings Release Classification · 100% confidence The document explicitly states it is a 'PRESS RELEASE' announcing financial results for the 'first half of 2024' (H1 2024). Key metrics like sales (€372 million), EBIT (€78.4 million), and earnings per share are highlighted. The text also mentions that the 'half-year report can be found on the company’s website'. This structure—a brief announcement summarizing key figures from a period shorter than a year, often preceding the full report—is characteristic of an Earnings Release (ER). While it discusses the half-year period, it is a summary press release, not the comprehensive 'Interim / Quarterly Report' (IR) itself, which would be much longer and more detailed. The presence of the link to the full report confirms this is the initial announcement. H1 2024
2024-08-06 English
Half-yearly financial report 2024
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled 'HALF-YEAR REPORT 2024 BIOTEST AG' and contains comprehensive financial sections including an 'Interim Management Report', 'Consolidated Statement of Income', 'Consolidated Statement of Financial Position', and 'Consolidated Cash Flow Statement' for the period ending 30 June 2024. It is a full interim financial report, not an announcement or a summary. H2 2024
2024-08-06 English
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is a presentation titled 'Half Year 2024 Results' for Biotest Group. It contains detailed financial highlights, income statements, balance sheets, cash flow data, and strategic guidance for the first half of 2024. Because it provides substantive financial data and analysis for an interim period (H1 2024) rather than just a summary or an announcement of a report, it is classified as an Interim/Quarterly Report. H2 2024
2024-08-06 English

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.